Perspective Therapeutics (CATX) Non Operating Interest Expenses (2023 - 2026)

Perspective Therapeutics has reported Non Operating Interest Expenses for 4 years, with the latest figure at $105000.0 in Q1 2026.

• Quarterly Non Operating Interest Expenses fell 17.97% year-over-year to $105000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229000.0 (up 55.78% YoY) and the FY2025 annual result came in at $376000.0, up 683.33% from the prior year.
• Non Operating Interest Expenses fell to $105000.0 in Q1 2026 per CATX's latest filing, from $128000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $128000.0 in Q1 2025 and troughed at -$73000.0 in Q4 2024.
• A 4-year average of $37666.7 and a median of $26000.0 in 2023 frame the typical range for Non Operating Interest Expenses.
• The sharpest annual moves came in 2024 and 2026: Non Operating Interest Expenses jumped 392.86% in 2024, then dropped 17.97% in 2026.
• Over 4 years, Non Operating Interest Expenses stood at $14000.0 in 2023, then tumbled by 621.43% to -$73000.0 in 2024, then surged by 275.34% to $128000.0 in 2025, then decreased by 17.97% to $105000.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $105000.0, $128000.0, and -$73000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.